Inogen's Q2 Was Okay-$4 Million EBITDA Only Works if the U.S. Wakes Up

A modest quarter raised the bar

Inogen's latest quarter mattered less for the growth rate and more for what management asked investors to believe next.

Inogen posted $95.1 million of second-quarter revenue, up 3.0% year over year on the headline, but only 0.6% at constant currency once you strip out forex. It was not a breakout quarter. The company also lifted full-year revenue guidance to $355 million to $361 million and raised full-year adjusted EBITDA guidance to about $4.0 million. That leaves investors with a tougher question: is this the start of stabilization, or just a better-reported quarter?

The bullish read is straightforward. A company usually does not raise a full-year EBITDA guide toward breakeven unless it sees underlying execution improving. Distributor traction in the U.S. and stronger international demand give the bull case something tangible to evaluate.

The bearish read is that reported growth was helped by foreign exchange, while the core business only edged higher. For now, this is less of a momentum story than a proof story.

International demand improved, but the U.S. is still the deciding factor

What improved in Q2

The clearest improvement came from international markets. International revenue reached $41.3 million, up 14.8% year over year. That is credible growth because it is showing up in reported revenue rather than in forward-looking language alone.

Inogen is also continuing to expand its international footprint. Earlier this year, it launched the Rove 6 in Brazil, broadening its market reach as it pursues growth outside the U.S.

Business quality also improved modestly. Gross profit margin rose to 45.5% from 44.8%, and adjusted EBITDA reached $2.4 million in the second quarter, up 15.2% year over year. Those figures suggest operating leverage is starting to improve, even if the growth is still modest.

What remains weak

The U.S. is still the part of the story investors cannot overlook. U.S. sales and rentals remained below the prior-year period. That matters because the U.S. is still the largest and most important market for Inogen.

A portion of the quarter's reported strength also came from favorable foreign-exchange rates, which helped the headline numbers without changing the underlying U.S. demand picture.

That is why the sequence matters. Inogen reiterated its full-year 2026 guidance in the first quarter and then raised its EBITDA target in the second. That does not prove the U.S. turnaround is here, but it does raise the burden of proof for the months ahead.

Why $4 million of EBITDA matters-and why it may not be enough

A few million dollars of EBITDA is not exciting by itself. But for Inogen, full-year adjusted EBITDA of approximately $4.0 million is a meaningful near-term test of whether the business can become more resilient.

The simple bull case is this: if investors begin to believe management can stabilize the U.S. channel, even slow top-line growth can become a margin-and-confidence story. The company does not need a miracle quarter. It needs evidence that the business model is becoming more durable.

That next step is not expected to happen all at once. Management has signaled that third-quarter 2026 revenue should be approximately in line with third-quarter 2025. In other words, the near-term test is less about explosive growth and more about whether the U.S. decline slows while international momentum and profitability carry more of the load.

What investors should watch next

This is still a watch-and-verify setup. Inogen may have gaining traction with U.S. distributors and an expanded product portfolio, but until that progress shows up in U.S. sales and rental revenue, the story still needs confirmation.

The next few quarters should focus on three things: - Whether U.S. sales stop trailing the prior year - Whether U.S. rentals stabilize - Whether improved margins and EBITDA are supported by repeatable cash generation

If those pieces improve together, the stock has a case to be re-rated. If not, this quarter will likely look like a decent pause rather than a real turning point.

Does the latest call change the thesis?

Not yet. The quarter improved the quality of the setup, but it did not settle the main debate. International demand is helping, profitability is moving the right way, and management is asking for more confidence by raising guidance. What the market still needs is proof that distributor progress in the U.S. can turn into real sales.

A replay of the call remains available through August 13, 2026. To access it, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13761255. Source: investor.inogen.com